Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat + 5-Azacitidine in MDS, CMML, or AML
NCT00946647Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2009
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of panobinostat in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), sponsored by Novartis. Started Dec 2009; status: completed.
02
Drugs
panobinostat
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00946647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00946647.